Trials / Completed
CompletedNCT01272817
Nonmyeloablative Allogeneic Transplant
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using Antithymocyte Globulin With Either Melphalan and Cladribine or Total Lymphoid Irradiation
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Scripps Health · Academic / Other
- Sex
- All
- Age
- 18 Years – 72 Years
- Healthy volunteers
- Not accepted
Summary
Allogeneic transplant from a matched sibling for the treatment of a variety of illnesses including bone marrow failure states, leukemias, myelodysplastic or myeloproliferative syndromes, lymphoma, or myeloma using a nonmyeloablative preparative regimen.
Detailed description
same
Conditions
- Aplastic Anemia
- Paroxysmal Nocturnal Hemoglobinuria
- Acute Myelogenous Leukemia
- Acute Lymphocytic Leukemia
- Myelodysplastic Syndrome
- Chronic Myelogenous Leukemia
- Chronic Lymphocytic Leukemia
- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- Mantle Cell Lymphoma
- Multiple Myeloma
- Waldenstrom Macroglobulinemia
- Breast Cancer
- Renal Cell Carcinoma
- Melanoma
- Sarcoma
- Ovarian Cancer
- Thymoma
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Nonmyeloablative Allogeneic Transplant | Cladribine 0.14 mg/kg/day for five days, melphalan 100 mg/m2 on one day |
| PROCEDURE | Nonmyeloablative Allogeneic Transplant | Total lymphoid irradiation 100cGy/day times 10 days (Monday through Friday) |
Timeline
- Start date
- 2001-10-01
- Primary completion
- 2015-10-01
- Completion
- 2015-10-01
- First posted
- 2011-01-10
- Last updated
- 2022-11-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01272817. Inclusion in this directory is not an endorsement.